GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » vTv Therapeutics Inc (NAS:VTVT) » Definitions » Cyclically Adjusted Revenue per Share

vTv Therapeutics (vTv Therapeutics) Cyclically Adjusted Revenue per Share : $8.88 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is vTv Therapeutics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

vTv Therapeutics's adjusted revenue per share for the three months ended in Mar. 2024 was $0.241. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $8.88 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-06-09), vTv Therapeutics's current stock price is $17.10. vTv Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $8.88. vTv Therapeutics's Cyclically Adjusted PS Ratio of today is 1.93.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of vTv Therapeutics was 3.14. The lowest was 1.93. And the median was 2.80.


vTv Therapeutics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for vTv Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

vTv Therapeutics Cyclically Adjusted Revenue per Share Chart

vTv Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

vTv Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 8.88

Competitive Comparison of vTv Therapeutics's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, vTv Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


vTv Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, vTv Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where vTv Therapeutics's Cyclically Adjusted PS Ratio falls into.



vTv Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, vTv Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.241/131.7762*131.7762
=0.241

Current CPI (Mar. 2024) = 131.7762.

vTv Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.245 100.560 0.321
201409 0.488 100.428 0.640
201412 1.139 99.070 1.515
201503 0.061 99.621 0.081
201506 0.564 100.684 0.738
201509 0.639 100.392 0.839
201512 0.987 99.792 1.303
201603 1.628 100.470 2.135
201606 0.762 101.688 0.987
201609 0.157 101.861 0.203
201612 0.157 101.863 0.203
201703 0.124 102.862 0.159
201706 0.054 103.349 0.069
201709 0.062 104.136 0.078
201712 0.963 104.011 1.220
201803 8.529 105.290 10.675
201806 9.853 106.317 12.212
201809 10.958 106.507 13.558
201812 10.231 105.998 12.719
201903 1.610 107.251 1.978
201906 2.608 108.070 3.180
201909 0.010 108.329 0.012
201912 0.007 108.420 0.009
202003 0.007 108.902 0.008
202006 0.000 108.767 0.000
202009 0.006 109.815 0.007
202012 5.003 109.897 5.999
202103 0.699 111.754 0.824
202106 0.006 114.631 0.007
202109 1.965 115.734 2.237
202112 0.005 117.630 0.006
202203 1.195 121.301 1.298
202206 0.005 125.017 0.005
202209 0.000 125.227 0.000
202212 0.004 125.222 0.004
202303 0.000 127.348 0.000
202306 0.000 128.729 0.000
202309 0.000 129.860 0.000
202312 0.000 129.419 0.000
202403 0.241 131.776 0.241

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


vTv Therapeutics  (NAS:VTVT) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

vTv Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=17.10/8.88
=1.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of vTv Therapeutics was 3.14. The lowest was 1.93. And the median was 2.80.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


vTv Therapeutics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of vTv Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


vTv Therapeutics (vTv Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
3980 Premier Drive, Suite 310, High Point, NC, USA, 27265
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. The company lead program is TTP399, an orally administered, small molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes.
Executives
Steven L. Tuch officer: Chief Financial Officer C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
John A Fry director C/O DELAWARE INVESTMENTS, 2005 MARKET ST. 34TH FL., PHILADELPHIA PA 19103
Jonathan Isaacsohn director C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Paul J Sekhri director, officer: President and CEO C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
Fahed Al-marzooqi director AL KHATEM TOWER, ABU DHABI GLOBAL MARKET, ABU DHABI C0 00000
Keith R. Harris director C/O MEIRAGTX - US, 430 EAST 29TH STREET, 10TH FLOOR, NEW YORK NY 10016
Hersh Kozlov director WOLF BLOCK SCHORR & SOLIS, 1940 RTE 70 E, CHERRY HILL NJ 08003
Howard L. Weiner director 4170 MENDENHALL OAKS PKWY, HIGH POINT NC 27265
Chandresh Harjivan director C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Al-nahyan Tahnoon Bin Zayed S. 10 percent owner OFFICE 2458, FLOOR 24, AL-SILA TOWER, ABU DHABI C0 00000
G42 Investments Ai Holdings Rsc Ltd. director, 10 percent owner OFFICE 801, FLOOR 8, AL KHATEM TOWER, ABU DHABI C0 00000
Barry K. Brown officer: Chief Accounting Officer C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Rich S. Nelson director, officer: Acting Chief Executive Officer C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Ronald O Perelman 10 percent owner 35 EAST 62ND STREET, NEW YORK NY 10021
Deepa Prasad director, officer: President and CEO C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, SUITE 310, HIGH POINT NC 27265

vTv Therapeutics (vTv Therapeutics) Headlines

From GuruFocus